SARS-CoV-2-specific B- and T-cell immunity in a population-based study of young Swedish adults
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Young adults are now considered major spreaders of coronavirus disease 2019 (COVID-19) disease. Although most young individuals experience mild to moderate disease, there are concerns of long-term adverse health effects. The impact of COVID-19 disease and to which extent population-level immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exists in young adults remain unclear.
OBJECTIVE: We conducted a population-based study on humoral and cellular immunity to SARS-CoV-2 and explored COVID-19 disease characteristics in young adults.
METHODS: We invited participants from the Swedish BAMSE (Barn [Children], Allergy Milieu, Stockholm, Epidemiology) birth cohort (age 24-27 years) to take part in a COVID-19 follow-up. From 980 participants (October 2020 to June 2021), we here present data on SARS-CoV-2 receptor-binding domain-specific IgM, IgA, and IgG titers measured by ELISA and on symptoms and epidemiologic factors associated with seropositivity. Further, SARS-CoV-2-specific memory B- and T-cell responses were detected for a subpopulation (n = 108) by ELISpot and FluoroSpot.
RESULTS: A total of 28.4% of subjects were seropositive, of whom 18.4% were IgM single positive. One in 7 seropositive subjects was asymptomatic. Seropositivity was associated with use of public transport, but not with sex, asthma, rhinitis, IgE sensitization, smoking, or body mass index. In a subset of representative samples, 20.7% and 35.0% had detectable SARS-CoV-2 specific B- and T-cell responses, respectively. B- and T-cell memory responses were clearly associated with seropositivity, but T-cell responses were also detected in 17.2% of seronegative subjects.
CONCLUSIONS: Assessment of IgM and T-cell responses may improve population-based estimations of SARS-CoV-2 infection. The pronounced surge of both symptomatic and asymptomatic infections among young adults indicates that the large-scale vaccination campaign should be continued.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:149 |
|---|---|
| Enthalten in: |
The Journal of allergy and clinical immunology - 149(2022), 1 vom: 15. Jan., Seite 65-75.e8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Björkander, Sophia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 14.01.2022 Date Revised 14.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaci.2021.10.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332355764 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332355764 | ||
| 003 | DE-627 | ||
| 005 | 20231225215414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaci.2021.10.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1107.xml |
| 035 | |a (DE-627)NLM332355764 | ||
| 035 | |a (NLM)34695490 | ||
| 035 | |a (PII)S0091-6749(21)01626-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Björkander, Sophia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2-specific B- and T-cell immunity in a population-based study of young Swedish adults |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.01.2022 | ||
| 500 | |a Date Revised 14.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Young adults are now considered major spreaders of coronavirus disease 2019 (COVID-19) disease. Although most young individuals experience mild to moderate disease, there are concerns of long-term adverse health effects. The impact of COVID-19 disease and to which extent population-level immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exists in young adults remain unclear | ||
| 520 | |a OBJECTIVE: We conducted a population-based study on humoral and cellular immunity to SARS-CoV-2 and explored COVID-19 disease characteristics in young adults | ||
| 520 | |a METHODS: We invited participants from the Swedish BAMSE (Barn [Children], Allergy Milieu, Stockholm, Epidemiology) birth cohort (age 24-27 years) to take part in a COVID-19 follow-up. From 980 participants (October 2020 to June 2021), we here present data on SARS-CoV-2 receptor-binding domain-specific IgM, IgA, and IgG titers measured by ELISA and on symptoms and epidemiologic factors associated with seropositivity. Further, SARS-CoV-2-specific memory B- and T-cell responses were detected for a subpopulation (n = 108) by ELISpot and FluoroSpot | ||
| 520 | |a RESULTS: A total of 28.4% of subjects were seropositive, of whom 18.4% were IgM single positive. One in 7 seropositive subjects was asymptomatic. Seropositivity was associated with use of public transport, but not with sex, asthma, rhinitis, IgE sensitization, smoking, or body mass index. In a subset of representative samples, 20.7% and 35.0% had detectable SARS-CoV-2 specific B- and T-cell responses, respectively. B- and T-cell memory responses were clearly associated with seropositivity, but T-cell responses were also detected in 17.2% of seronegative subjects | ||
| 520 | |a CONCLUSIONS: Assessment of IgM and T-cell responses may improve population-based estimations of SARS-CoV-2 infection. The pronounced surge of both symptomatic and asymptomatic infections among young adults indicates that the large-scale vaccination campaign should be continued | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 disease | |
| 650 | 4 | |a IgA | |
| 650 | 4 | |a IgG | |
| 650 | 4 | |a IgM | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a asthma | |
| 650 | 4 | |a memory B cells | |
| 650 | 4 | |a memory T cells | |
| 650 | 4 | |a population-based cohort | |
| 650 | 4 | |a risk factors | |
| 650 | 4 | |a young adults | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Du, Likun |e verfasserin |4 aut | |
| 700 | 1 | |a Zuo, Fanglei |e verfasserin |4 aut | |
| 700 | 1 | |a Ekström, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yating |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Sherina, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Schoutens, Lisanne |e verfasserin |4 aut | |
| 700 | 1 | |a Andréll, Juni |e verfasserin |4 aut | |
| 700 | 1 | |a Andersson, Niklas |e verfasserin |4 aut | |
| 700 | 1 | |a Georgelis, Antonios |e verfasserin |4 aut | |
| 700 | 1 | |a Bergström, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Marcotte, Harold |e verfasserin |4 aut | |
| 700 | 1 | |a Kull, Inger |e verfasserin |4 aut | |
| 700 | 1 | |a Hammarström, Lennart |e verfasserin |4 aut | |
| 700 | 1 | |a Melén, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Pan-Hammarström, Qiang |e verfasserin |4 aut | |
| 700 | 0 | |a BAMSE COVID-19 study group |e verfasserin |4 aut | |
| 700 | 1 | |a Almqvist, Catarina |e investigator |4 oth | |
| 700 | 1 | |a Andersson, Niklas |e investigator |4 oth | |
| 700 | 1 | |a Ballardini, Natalia |e investigator |4 oth | |
| 700 | 1 | |a Bergström, Anna |e investigator |4 oth | |
| 700 | 1 | |a Björkander, Sophia |e investigator |4 oth | |
| 700 | 1 | |a Brodin, Petter |e investigator |4 oth | |
| 700 | 1 | |a Castel, Anna |e investigator |4 oth | |
| 700 | 1 | |a Ekström, Sandra |e investigator |4 oth | |
| 700 | 1 | |a Georgelis, Antonios |e investigator |4 oth | |
| 700 | 1 | |a Hammarström, Lennart |e investigator |4 oth | |
| 700 | 1 | |a Pan-Hammarström, Qiang |e investigator |4 oth | |
| 700 | 1 | |a Hallberg, Jenny |e investigator |4 oth | |
| 700 | 1 | |a Jansson, Christer |e investigator |4 oth | |
| 700 | 1 | |a Kere, Maura |e investigator |4 oth | |
| 700 | 1 | |a Kull, Inger |e investigator |4 oth | |
| 700 | 1 | |a Lauber, André |e investigator |4 oth | |
| 700 | 1 | |a Lövquist, Alexandra |e investigator |4 oth | |
| 700 | 1 | |a Melén, Erik |e investigator |4 oth | |
| 700 | 1 | |a Mjösberg, Jenny |e investigator |4 oth | |
| 700 | 1 | |a Mogensen, Ida |e investigator |4 oth | |
| 700 | 1 | |a Palmberg, Lena |e investigator |4 oth | |
| 700 | 1 | |a Pershagen, Göran |e investigator |4 oth | |
| 700 | 1 | |a Roxhed, Niclas |e investigator |4 oth | |
| 700 | 1 | |a Schwenk, Jochen |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of allergy and clinical immunology |d 1971 |g 149(2022), 1 vom: 15. Jan., Seite 65-75.e8 |w (DE-627)NLM000018449 |x 1097-6825 |7 nnns |
| 773 | 1 | 8 | |g volume:149 |g year:2022 |g number:1 |g day:15 |g month:01 |g pages:65-75.e8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaci.2021.10.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 149 |j 2022 |e 1 |b 15 |c 01 |h 65-75.e8 | ||